Detail of the clinical trial
| Title of the trial | A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses |
|---|---|
| EudraCT number | 2014-001617-12 |
| Protocol number | AP24534-14-203 |
| Sponsor | ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA 02139, United States of America |
| Indications | Hemato-oncology |
| Diagnosis | Chronic Myeloid Leukemia |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2016 |
| Date of approval by Institute (SÚKL) | 17.1.2017 |
| Date of approval by EC | |
| Date of initiation CT in ČR | |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
Ústav hematologie a krevní transfúze, U Nemocnice 2094/1,Praha 2,12820 Fakultní nemocnice Olomouc, I.P.Pavlova 6,Olomouc,77520 |
cz